CEM Creates New Division for Chemical Synthesis Scale Up
News Sep 23, 2005
CEM Corporation has announced the formation of a division within the company that will be focused on developing systems for scaling up reactions performed using microwave synthesis.
The Chemical Synthesis Scale-up Division will represent an investment of at least $10 million over the next five years for the Company and will be charged with developing systems to produce multi-kilogram to manufacturing scale quantities of synthesized materials.
"Now that small scale microwave synthesis has become an accepted method, we are ready to take it to the next level," said Michael J. Collins, President & CEO of CEM Corporation.
"The formation of this new division will enable CEM to offer a complete microwave synthesis solution from discovery phase to full production scale and will have a major impact on companies specializing in pharmaceutical sciences, biosciences, specialty chemicals and polymer synthesis."
CEM's new division will have an in-house team of chemists, chemical engineers, and design engineers to develop the line of scale-up systems.
In addition, the Company is pursuing strategic collaborations with major companies that utilize large scale chemical synthesis, ensuring well-designed product offerings.
"CEM's development of microwave synthesis systems for scale-up began with Voyager three years ago and is evolving into an entire family of scale-up solutions," said Michael Collins, Jr.
"We already have a strong R&D pipeline of products that we will begin offering over the next 12 months, which will culminate in production scale equipment in the next five years."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018